Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (...

Por Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C.
Publicado em 2010

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

Por Chiappori, A. A., Kolevska, T., Spigel, D. R., Hager, S., Rarick, M., Gadgeel, S., Blais, N., Von Pawel, J., Hart, L., Reck, M., Bassett, E., Burington, B., Schiller, J. H.
Publicado no Ann Oncol (2015)

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

Por McKeage, M J, Von Pawel, J, Reck, M, Jameson, M B, Rosenthal, M A, Sullivan, R, Gibbs, D, Mainwaring, P N, Serke, M, Lafitte, J-J, Chouaid, C, Freitag, L, Quoix, E
Publicado em 2008

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

Por Paz-Ares, L, Ross, H, O'Brien, M, Riviere, A, Gatzemeier, U, Von Pawel, J, Kaukel, E, Freitag, L, Digel, W, Bischoff, H, García-Campelo, R, Iannotti, N, Reiterer, P, Bover, I, Prendiville, J, Eisenfeld, A J, Oldham, F B, Bandstra, B, Singer, J W, Bonomi, P
Publicado em 2008